The Impact of Type 2 Diabetes in Parkinson's Disease

Importance: Type 2 diabetes (T2DM) is an established risk factor for developing Parkinson's disease (PD) but its effect on disease progression is not well understood. Objective: To examine the effects of co-morbid T2DM on Parkinson's disease progression and quality of life. Design: We analysed data from the Tracking Parkinson's study, a large multi-centre prospective study in the UK. Participants: The study included 1930 adults with recent onset PD, recruited between February 2012 and May 2014, and followed up regularly thereafter. Exposure: A diagnosis of pre-existing T2DM was based on self-report at baseline. After controlling for confounders, an evaluation of how T2DM affects PD was performed by comparing symptom severity scores; and analyses using multivariable mixed models was used to determine the effects of T2DM on Parkinson's disease progression. Main Outcomes and Measures: The impact of T2DM on Parkinsons disease severity was derived from scores collected using the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Non-Motor Symptoms Scale (NMSS), Montreal Cognitive Assessment (MoCA), Questionnaire for impulsive-compulsive disorders in PD (QUIP), Leeds Anxiety and Depression Scale (LADS), and Schwab and England ADL scale. Results: We identified 167 (8.7%) patients with PD and T2DM (PD+T2DM) and 1763 (91.3%) with PD without T2DM (PD). Patients with T2DM had more severe motor symptoms, as assessed by MDS-UPDS III 25.8 (0.9) vs 22.5 (0.3) p=0.002, had significantly faster motor symptom progression over time (p=0.012), and T2DM was an independent predictor for the development of substantial gait impairment (HR 1.55, CI 1.07-2.23, p=0.020). Patients were more likely to have loss of independence (OR 2.08, CI 1.34-3.25, p=0.001); and depression (OR 1.62, CI 1.10-2.39, p=0.015), and developed worsening mood (p=0.041) over time compared to the PD group. T2DM was also an independent predictor for the development mild cognitive impairment (HR 1.7, CI 1.24-2.51, p=0.002) over time Conclusions and relevance: T2DM is associated with faster disease progression in PD, highlighting an interaction between these two diseases. As it is a potentially modifiable, metabolic state, with multiple peripheral and central targets for intervention, it may represent a target for ameliorating parkinsonian symptoms, and progression to disability and dementia.

[1]  R. Barker,et al.  Tracking Parkinson’s: Study Design and Baseline Patient Data , 2015, Journal of Parkinson's disease.

[2]  Huaxi Xu,et al.  Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription , 2009, Proceedings of the National Academy of Sciences.

[3]  S. Shah,et al.  Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus , 2018, Movement disorders : official journal of the Movement Disorder Society.

[4]  D. Bennett,et al.  Diabetes mellitus and progression of rigidity and gait disturbance in older persons , 2004, Neurology.

[5]  Kristine Yaffe,et al.  Macro- and Microstructural Magnetic Resonance Imaging Indices Associated With Diabetes Among Community-Dwelling Older Adults , 2013, Diabetes Care.

[6]  O Johnell,et al.  Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. , 1992, Age and ageing.

[7]  B. Penninx,et al.  Incident Major Depressive Disorder Predicted by Three Measures of Insulin Resistance: A Dutch Cohort Study. , 2021, The American journal of psychiatry.

[8]  L. Moran,et al.  Towards a pathway definition of Parkinson’s disease: a complex disorder with links to cancer, diabetes and inflammation , 2008, Neurogenetics.

[9]  B. Penninx,et al.  Association of Insulin Resistance With Depression Severity and Remission Status: Defining a Metabolic Endophenotype of Depression. , 2020, JAMA psychiatry.

[10]  I. Hertz-Picciotto,et al.  Methods of covariate selection: directed acyclic graphs and the change-in-estimate procedure. , 2009, American journal of epidemiology.

[11]  Thomas Foltynie,et al.  The natural history of treated Parkinson's disease in an incident, community based cohort , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  Alan A. Wilson,et al.  Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans , 2015, The international journal of neuropsychopharmacology.

[13]  L. Groop,et al.  Subjective Sleep Complaints Are AssociatedWith Insulin Resistance in IndividualsWithout Diabetes The PPP-Botnia Study , 2012 .

[14]  M. Luquin,et al.  Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies , 2018, Acta Neuropathologica.

[15]  N. V. D. Berge,et al.  Neuropathological evidence of body-first vs. brain-first Lewy body disease , 2021, Neurobiology of Disease.

[16]  M. Hamilton,et al.  The Leeds Scales for the Self-Assessment of Anxiety and Depression , 1976, British Journal of Psychiatry.

[17]  D. Brooks,et al.  Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. , 2020, Brain : a journal of neurology.

[18]  Z. Gan-Or,et al.  Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression , 2021, Movement disorders : official journal of the Movement Disorder Society.

[19]  T. Montine,et al.  Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures , 2019, Clinical parkinsonism & related disorders.

[20]  R. Albin,et al.  Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. , 2014, Parkinsonism & related disorders.

[21]  T. Foltynie,et al.  Insulin resistance and Parkinson’s disease: A new target for disease modification? , 2016, Progress in Neurobiology.

[22]  D. Benninger,et al.  Physical Therapy for Freezing of Gait and Gait Impairments in Parkinson Disease: A Systematic Review , 2020, PM & R : the journal of injury, function, and rehabilitation.

[23]  Claudio Soto,et al.  Type 2 diabetes as a protein misfolding disease. , 2015, Trends in molecular medicine.

[24]  S. Lai.  Reader response: Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study , 2019, Neurology.

[25]  R. Albin,et al.  Diabetes is associated with postural instability and gait difficulty in Parkinson disease. , 2013, Parkinsonism & related disorders.

[26]  Y. Sohn,et al.  Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease. , 2021, Brain : a journal of neurology.

[27]  B. McEwen,et al.  Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance , 2020, Molecular Psychiatry.

[28]  F. Niccolini,et al.  Diabetes mellitus and Parkinson disease , 2018, Neurology.

[29]  K. Freedland,et al.  The prevalence of comorbid depression in adults with diabetes: a meta-analysis. , 2001, Diabetes care.

[30]  B. Everitt,et al.  Involvement of the Dorsal Striatum in Cue-Controlled Cocaine Seeking , 2005, The Journal of Neuroscience.

[31]  Jose A. Santiago,et al.  Integrative Network Analysis Unveils Convergent Molecular Pathways in Parkinson's Disease and Diabetes , 2013, PloS one.

[32]  L. Seeberger,et al.  Reliability of measurements of patient health status: a comparison of physician, patient, and caregiver ratings. , 2002, Parkinsonism & related disorders.

[33]  T. Friede,et al.  Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa) , 2018, Movement disorders : official journal of the Movement Disorder Society.

[34]  J. Kordower,et al.  Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA , 2018, Molecular Neurobiology.

[35]  J. Kril,et al.  Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson’s disease , 2018, Journal of Clinical Neuroscience.

[36]  B. McEwen,et al.  Insulin resistance, an unmasked culprit in depressive disorders: Promises for interventions , 2017, Neuropharmacology.

[37]  R. Barker,et al.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines , 2012, Movement disorders : official journal of the Movement Disorder Society.

[38]  Yulin Deng,et al.  High-fat diet causes increased endogenous neurotoxins and phenotype of Parkinson's disease in mice. , 2019, Acta biochimica et biophysica Sinica.

[39]  Alan C. Evans,et al.  Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease. , 2019, Parkinsonism & related disorders.

[40]  Pengwen Wang,et al.  Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer’s disease , 2021, 3 Biotech.

[41]  L. Groop,et al.  Subjective Sleep Complaints Are Associated With Insulin Resistance in Individuals Without Diabetes , 2012, Diabetes Care.

[42]  S. Jick,et al.  Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer's Disease: A Population‐Based Case–Control Study , 2012, Journal of the American Geriatrics Society.

[43]  Wei Song,et al.  Effect of diabetes control status on the progression of Parkinson’s disease: A prospective study , 2021, Annals of clinical and translational neurology.

[44]  F. Oriente,et al.  The Relevance of Insulin Action in the Dopaminergic System , 2019, Front. Neurosci..

[45]  Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein , 2021, Acta neuropathologica communications.

[46]  R. Albin,et al.  Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease. , 2016, Academic radiology.

[47]  H. Lashuel,et al.  Glycation potentiates &agr;-synuclein-associated neurodegeneration in synucleinopathies , 2017, Brain : a journal of neurology.

[48]  B. Högl,et al.  Sleep in Parkinson’s disease , 2019, Neuropsychopharmacology.

[49]  Qingxia Chen,et al.  Too many covariates and too few cases? – a comparative study , 2016, Statistics in medicine.

[50]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[51]  S. Grover,et al.  Psychiatric aspects of Parkinson's disease , 2015, Journal of neurosciences in rural practice.

[52]  Jose A. Santiago,et al.  Shared dysregulated pathways lead to Parkinson's disease and diabetes. , 2013, Trends in molecular medicine.

[53]  O. Tysnes,et al.  Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study. , 2017, Parkinsonism & related disorders.

[54]  C. Taghibiglou,et al.  Elevated nuclear phosphatase and tensin homolog (PTEN) and altered insulin signaling in substantia nigral region of patients with Parkinson’s disease , 2018, Neuroscience Letters.

[55]  R. Barker,et al.  Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[56]  I. Horváth,et al.  Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson’s disease , 2016, Proceedings of the National Academy of Sciences.

[57]  J. Assmus,et al.  Glitazone use associated with reduced risk of Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.

[58]  D. D. Di Monte,et al.  Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation , 2014, Cell Death and Disease.

[59]  A Hofman,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[60]  E. Gatto,et al.  Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review , 2019, Front. Neurol..

[61]  S. Amiel,et al.  Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study. , 2016, Primary care diabetes.

[62]  L. Egede,et al.  The Association Between Multimorbidity and Quality of Life, Health Status and Functional Disability , 2016, The American journal of the medical sciences.

[63]  D. Munoz,et al.  Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes , 2019, Front. Psychiatry.

[64]  Daniel Weintraub,et al.  Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.